Is a cure possible for a patient with ovarian cancer after complete surgical resection of liver metastases and peritoneal carcinomatosis who is receiving maintenance therapy?

Is Cure Possible in Advanced Ovarian Cancer?

While complete cure remains rare in advanced ovarian cancer with liver metastases and peritoneal carcinomatosis, approximately 20% of women with advanced-stage disease can achieve long-term survival beyond 12 years and are effectively cured, particularly when maximal cytoreductive surgery achieves no visible residual disease combined with optimal chemotherapy and appropriate maintenance therapy 1.

Understanding the Concept of Cure

The probability of cure depends entirely on whether all cancer cells are eliminated through the combination of surgery and chemotherapy 1. If no cancer cells remain after initial therapy, cure is expected. However, if residual cancer cells persist, recurrence is likely. The key determinant is achieving a cancer-free state through:

• Complete macroscopic resection during cytoreductive surgery
• Effective systemic chemotherapy to eliminate microscopic disease
• Appropriate maintenance therapy to prevent recurrence

Surgical Considerations for Cure

Resection of isolated parenchymal liver metastases should be performed to achieve complete cytoreduction 2. This is critical because:

• Complete surgical resection (no visible residual disease) is the strongest predictor of cure
• Enlarged or suspicious lymph nodes must be removed to achieve complete resection 2
• The goal is maximal debulking surgery, which when combined with intraperitoneal chemotherapy, could potentially achieve cures in up to 50% of women with advanced-stage disease 1

Maintenance Therapy Strategy

After achieving complete resection and response to chemotherapy, maintenance therapy selection depends on molecular characteristics:

For BRCA-mutated or HRD-positive tumors:

• PARP inhibitors (olaparib, niraparib, or rucaparib) with or without bevacizumab are Category 1 recommendations for patients in CR/PR/NED after platinum-based chemotherapy 3
• Olaparib is recommended for 2 years; niraparib for 3 years 2
• In BRCA-mutated patients, 67% remained alive at 7 years with olaparib maintenance versus 46% with placebo 3

For HRD-positive tumors without BRCA mutations:

• Bevacizumab plus olaparib is Category 1 for those who received bevacizumab in first-line therapy 3
• 5-year overall survival was 65.5% versus 48.4% with combination versus bevacizumab alone 3

For HRD-negative tumors:

• Platinum-based chemotherapy with bevacizumab followed by bevacizumab maintenance 2
• PARP inhibitors provide minimal benefit (approximately 3 months median survival benefit) 3

Critical Caveats

The term "cure" must be qualified: While 20% of patients achieve long-term survival beyond 12 years, this represents effective cure rather than guaranteed permanent disease eradication 1. The presence of liver metastases and peritoneal carcinomatosis indicates stage III-IV disease, where cure rates are lower than earlier stages.

Complete cytoreduction is non-negotiable: If complete macroscopic resection cannot be achieved, the probability of cure drops dramatically. Patients should undergo evaluation by a gynecologic oncologist experienced in complex cytoreductive procedures 2.

Molecular testing is essential: HRD testing and BRCA mutation status directly determine which maintenance strategy offers the best chance of long-term disease control 3. Without this information, treatment selection is suboptimal.

The realistic expectation for your patient is that cure is possible but not probable. With complete surgical resection, appropriate chemotherapy, and molecularly-guided maintenance therapy, long-term disease-free survival extending beyond 10-12 years can be achieved in a subset of patients, representing functional cure 1.